{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-100787","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.143332+00:00","generated_at":"2026-06-10T17:33:04.821375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rezolute reports FY2023 net loss of $51.8M; Phase 3 for RZ358 to start Q4 2023","bullets":["Cash and equivalents $16.0M, marketable securities $102.3M as of June 30, 2023.","Full year net loss $51.8M vs $41.1M prior year; R&D spend $43.8M (up from $32.5M).","Phase 3 sunRIZE study for RZ358 in congenital HI to initiate Q4 2023; topline data H1 2025.","Phase 2 study of RZ402 for diabetic macular edema ongoing; results expected Q1 2024.","Q4 net loss $12.7M vs $9.4M in prior year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-100787","json":"https://secwatch.observer/filing/0001104659-23-100787.json","markdown":"https://secwatch.observer/filing/0001104659-23-100787.md","text":"https://secwatch.observer/filing/0001104659-23-100787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923100787/0001104659-23-100787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923100787/tm2325841d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:33:04.821375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f65a73621a61b8c5529fae52998ae50941171b1c","claim":"Rezolute, Inc. reported financial results for the fourth quarter and full fiscal year ended June 30, 2023.","evidence_excerpt":"On September 14, 2023, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465923100787/0001104659-23-100787-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full fiscal year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}